Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial.

@article{Cummings1998EffectOA,
  title={Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial.},
  author={Steven R. Cummings and Dennis M. Black and Desmond E Thompson and William B. Applegate and Elizabeth Barrett-Connor and Thomas A. Musliner and Lisa Palermo and Ronald Prineas and Susan M. Rubin and J C Scott and Thomas M. Vogt and Robert B. Wallace and A. John Yates and Andrea Z. LaCroix},
  journal={JAMA},
  year={1998},
  volume={280 24},
  pages={
          2077-82
        }
}
CONTEXT Alendronate sodium reduces fracture risk in postmenopausal women who have vertebral fractures, but its effects on fracture risk have not been studied for women without vertebral fractures. [] Key MethodDESIGN Randomized, blinded, placebo-controlled trial. SETTING Eleven community-based clinical research centers.

Figures and Tables from this paper

Effect of alendronate on vertebral fracture risk in women with bone mineral density T scores of-1.6 to -2.5 at the femoral neck: the Fracture Intervention Trial.

In women with low bone mass who do not meet the bone mineral density criterion for osteoporosis, alendronate is effective in reducing the risk of vertebral fractures.

Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group.

Reductions in fracture risk during treatment with alendronate are consistent in women with existing vertebral fractures and those without such fractures but with bone mineral density in the osteoporotic range.

Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk.

Denosumab reduced the incidence of new vertebral and hip fractures in postmenopausal women with osteoporosis at higher risk for fracture, and these results highlight the consistent antifracture efficacy of denosumAB in patients with varying degrees of fracture risk.

Risk of fracture among women who lose bone density during treatment with alendronate. The Fracture Intervention Trial

Among patients who adhere to treatment with alendronate, even those who lose BMD benefit from a substantial reduction in risk of vertebral fracture, and the reduction in bone turnover induced by alendronsate might be more important than BMD changes.

Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group.

Women with increases of > or =3% in BMD during the first 1 or 2 years of alendronate treatment had the lowest incidence of new vertebral fractures, suggesting that, among women taking antiresorptive agents, greater increases in B MD are associated with lower risk of new fractures.

Effects of calcium supplementation on clinical fracture and bone structure: results of a 5-year, double-blind, placebo-controlled trial in elderly women.

BACKGROUND Increased dietary calcium intake has been proposed as a population-based public health intervention to prevent osteoporotic fractures. We have examined whether calcium supplementation

a repository copy of Pharmacologic intervention for prevention of fractures in osteopenic and osteoporotic postmenopausal women: Systemic review and meta-analysis

Overall results of limited studies for non-bisphosphonate drugs showed increased BMD and raloxifene signiicantly decreases the risk of subsequent clinical vertebral fractures in postmenopausal women with osteopenia or osteoporosis.

Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.

The data suggest that risedronate therapy is effective and well tolerated in the treatment of women with established postmenopausal osteoporosis.
...

References

SHOWING 1-10 OF 27 REFERENCES

The Association of Radiographically Detected Vertebral Fractures with Back Pain and Function: A Prospective Study

This study examined the effect of incident vertebral fractures on back pain and back-related functional limitations in a large community-based sample of elderly women who underwent serial spinal radiography and annual assessments of backPain and disability over the same period.

Prevention of bone loss with alendronate in postmenopausal women under 60 years of age.

Background Estrogen-replacement therapy prevents osteoporosis in postmenopausal women by inhibiting bone resorption, but the balance between its long-term risks and benefits remains unclear. Whether

Alendronate Prevents Postmenopausal Bone Loss in Women without Osteoporosis: A Double-Blind, Randomized, Controlled Trial

A 3-year randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy of alendronate therapy in preventing bone loss in healthy women who had recently experienced menopause.

Markers of bone resorption predict hip fracture in elderly women: The EPIDOS prospective study

  • P. GarneroE. Hausherr P. Delmas
  • Medicine
    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
  • 1996
Elderly women are characterized by increased bone turnover, and some markers of bone resorption predict the subsequent risk of hip fracture independently of hip BMD, which may be useful to improve the assessment of the risk of Hip fracture in elderly women.

Prevalence of low femoral bone density in older U.S. women from NHANES III

  • A. LookerC. Johnston R. Lindsay
  • Medicine
    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
  • 1995
The first data on BMD from a nationally representative sample of older women show a substantial number with low femoral BMD, including the majority of white women but the number of minority women with low BMD is not trivial.

Prevalence of Low Femoral Bone Density in Older U.S. Adults from NHANES III

  • A. LookerE. Orwoll S. Heyse
  • Medicine
    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
  • 1997
Dual‐energy X‐ray absorptiometry measurements of femoral bone mineral density (BMD) from the third National Health and Nutrition Examination Survey (NHANES III, 1988–1994) are used to estimate the overall scope of the disease in the older U.S. population and explore different approaches for defining low BMD in older men in that age range.